Researchers performed a examine to check once-weekly semaglutide 1.zero mg with exenatide prolonged launch (ER) 2.zero mg in sufferers with sort 2 diabetes to see about their security and effectiveness.
Semaglutide once-weekly is within the GLP-1 receptor agonist class of diabetes medicine marketed as Ozempic by Novo Nordisk for the therapy of sort 2 diabetes in adults.
Exenatide ER is additionally a once-weekly GLP-1 receptor agonist marketed as Bydureon by AstraZeneca for sort 2 diabetes therapy.
The researchers lead a part 3a, open-label, parallel-group, randomized managed trial with 813 contributors with sort 2 diabetes taking oral diabetes drugs. These sufferers have been randomly chosen to take both semaglutide 1.zero mg or exenatide ER 2.zero mg for 56 weeks complete.
The fundamental object was to take a look at adjustments in A1c ranges between the beginning of the trial and week 56.
Which Diabetes Drug Was Safer and More Effective?
Mean A1c at baseline among the many contributors was eight.three%. According to this examine’s outcomes, these on semaglutide lowered the imply A1c ranges by 1.5% and people on exenatide ER by .9%.
Regarding physique weight of the contributors, imply physique weight was 95.eight kg at baseline and that imply was decreased by 5.6 kg with semaglutide and 1.9 kg with exenatide ER.
How most of the contributors acquired their A1c beneath 7%? 67% of these taking semaglutide and solely 40% of these on exenatide ER.
The researchers say that each remedies “had similar safety profiles, but gastrointestinal adverse events were more common in semaglutide-treated subjects (41.8%) than in exenatide ER–treated subjects (33.3%)” Also, reactions on the injection-site have been extra frequent for these on exenatide ER (22%) than these with semaglutide (1.2%
The examine authors conclude that the superior drug in line with this examine got here out to be semaglutide 1.zero mg when it got here to bettering blood sugars and decreasing physique weight after 56 weeks. The two medicine are comparable when it comes to security profiles.
“These results indicate that semaglutide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs,” state the authors.
Post Views: 191
Read extra about A1c, AstraZeneca, exenatide, GLP-1, Novo Nordisk, Ozempic (semaglutide), sort 2 diabetes medicine.